Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 1/2014

01-02-2014

Targeting Voltage Gated Sodium Channels NaV1.7, NaV1.8, and NaV1.9 for Treatment of Pathological Cough

Authors: Yukiko Muroi, Bradley J. Undem

Published in: Lung | Issue 1/2014

Login to get access

Abstract

Recent advances in our understanding of voltage-gated sodium channels (NaVs) lead to the rational hypothesis that drugs capable of selective blockade of NaV subtypes may be a safe and effective strategy for the treatment of unwanted cough. Among the nine NaV subtypes (NaV1.1–NaV1.9), the afferent nerves involved in initiating cough, in common with nociceptive neurons in the somatosensory system, express mainly NaV1.7, NaV1.8, and NaV1.9. Although knowledge about the effect of selectively blocking these channels on the cough reflex is limited, their biophysical properties indicate that each may contribute to the hypertussive and allotussive state that typifies subacute and chronic nonproductive cough.
Literature
1.
Catterall WA, Raman IM, Robinson HP, Sejnowski TJ, Paulsen O (2012) The Hodgkin–Huxley heritage: from channels to circuits. J Neurosci 32(41):14064–14073PubMedCentralCrossRefPubMed
2.
3.
4.
Trochtenberg S (1994) Nebulized lidocaine in the treatment of refractory cough. Chest 105(5):1592–1593CrossRefPubMed
5.
Howard P, Cayton RM, Brennan SR, Anderson PB (1977) Lignocaine aerosol and persistent cough. Br J Dis Chest 71(1):19–24CrossRefPubMed
6.
Chong CF, Chen CC, Ma HP, Wu YC, Chen YC, Wang TL (2005) Comparison of lidocaine and bronchodilator inhalation treatments for cough suppression in patients with chronic obstructive pulmonary disease. Emerg Med J 22(6):429–432PubMedCentralCrossRefPubMed
7.
Dicpinigaitis PV, Gayle YE, Solomon G, Gilbert RD (2009) Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough. Respir Med 103(6):902–906CrossRefPubMed
8.
Canning BJ, Mazzone SB, Meeker SN, Mori N, Reynolds SM, Undem BJ (2004) Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetized guinea-pigs. J Physiol 557:543–558PubMedCentralCrossRefPubMed
9.
Fox AJ, Barnes PJ, Urban L, Dray A (1993) An in vitro study of the properties of single vagal afferents innervating guinea-pig airways. J Physiol 469:21–35PubMedCentralCrossRefPubMed
10.
Carr MJ, Kollarik M, Meeker SN, Undem BJ (2003) A role for TRPV1 in bradykinin-induced excitation of vagal airway afferent nerve terminals. J Pharmacol Exp Ther 304:1275–1279CrossRefPubMed
11.
Chuaychoo B, Lee MG, Kollarik M, Pullmann R Jr, Undem BJ (2006) Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs. J Physiol 575(Pt 2):481–490PubMedCentralCrossRefPubMed
12.
Coleridge JCG, Coleridge HM (1984) Afferent vagal C-fiber innervation of the lungs and airways and its functional significance. Rev Physiol Biochem Pharmacol 99:1–110PubMed
13.
Taylor-Clark T, Undem BJ (2006) Transduction mechanisms in airway sensory nerves. J Appl Physiol 101(3):950–959CrossRefPubMed
14.
Undem BJ, Chuaychoo B, Lee MG, Weinreich D, Myers AC, Kollarik M (2004) Subtypes of vagal afferent C-fibres in guinea-pig lungs. J Physiol 556(pt 3):905–917PubMedCentralCrossRefPubMed
15.
16.
Kwong K, Carr MJ, Gibbard A, Savage TJ, Singh K, Jing J, Meeker S, Undem BJ (2008) Voltage-gated sodium channels in nociceptive versus non-nociceptive nodose vagal sensory neurons innervating guinea pig lungs. J Physiol 586(5):1321–1336PubMedCentralCrossRefPubMed
17.
Muroi Y, Ru F, Kollarik M, Canning BJ, Hughes SA, Walsh S, Sigg M, Carr MJ, Undem BJ (2011) Selective silencing of Na(V)1.7 decreases excitability and conduction in vagal sensory neurons. J Physiol 589(Pt 23):5663–5676PubMedCentralCrossRefPubMed
18.
Raymond CK, Castle J, Garrett-Engele P, Armour CD, Kan Z, Tsinoremas N, Johnson JM (2004) Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. J Biol Chem 279(44):46234–46241CrossRefPubMed
19.
Lai J, Porreca F, Hunter JC, Gold MS (2004) Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 44:371–397CrossRefPubMed
20.
Priest BT, Kaczorowski GJ (2007) Subtype-selective sodium channel blockers promise a new era of pain research. Proc Natl Acad Sci USA 104(20):8205–8206PubMedCentralCrossRefPubMed
21.
Nardi A, Damann N, Hertrampf T, Kless A (2013) Advances in targeting voltage-gated sodium channels with small molecules. ChemMedChem 7(10):1712–1740CrossRef
22.
Farrag KJ, Costa SK, Docherty RJ (2002) Differential sensitivity to tetrodotoxin and lack of effect of prostaglandin E2 on the pharmacology and physiology of propagated action potentials. Br J Pharmacol 135(6):1449–1456PubMedCentralCrossRefPubMed
23.
24.
Mazzone SB, Reynolds SM, Mori N, Kollarik M, Farmer DG, Myers AC, Canning BJ (2009) Selective expression of a sodium pump isozyme by cough receptors and evidence for its essential role in regulating cough. J Neurosci 29(43):13662–13671PubMedCentralCrossRefPubMed
25.
Muroi Y, Ru F, Chou YL, Carr MJ, Undem BJ, Canning BJ (2013) Selective inhibition of vagal afferent nerve pathways regulating cough using NaV1.7 shRNA silencing in guinea pig nodose ganglia. Am J Physiol Regul Integr Comp Physiol 304:R1017–R1023PubMedCentralCrossRefPubMed
26.
Stamboulian S, Choi JS, Ahn HS, Chang YW, Tyrrell L, Black JA, Waxman SG, Dib-Hajj SD (2010) ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J Neurosci 30(5):1637–1647CrossRefPubMed
27.
Strickland IT, Martindale JC, Woodhams PL, Reeve AJ, Chessell IP, McQueen DS (2008) Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain 12(5):564–572CrossRefPubMed
28.
Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR (2007) Loss-of-function mutations in the NaV1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71(4):311–319CrossRefPubMed
29.
Weiss J, Pyrski M, Jacobi E, Bufe B, Willnecker V, Schick B, Zizzari P, Gossage SJ, Greer CA, Leinders-Zufall T, Woods CG, Wood JN, Zufall F (2011) Loss-of-function mutations in sodium channel NaV1.7 cause anosmia. Nature 472(7342):186–190PubMedCentralCrossRefPubMed
30.
Schild JH, Clark JW, Hay M, Mendelowitz D, Andresen MC, Kunze DL (1994) A- and C-type rat nodose sensory neurons: model interpretations of dynamic discharge characteristics. J Neurophysiol 71(6):2338–2358PubMed
31.
32.
Kwong K, Lee LY (2002) PGE2 sensitizes cultured pulmonary vagal sensory neurons to chemical and electrical stimuli. J Appl Physiol 93(4):1419–1428CrossRefPubMed
33.
Maher SA, Birrell MA, Belvisi MG (2009) Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med 180(10):923–928PubMedCentralCrossRefPubMed
34.
Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS (2007) A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 104(20):8520–8525PubMedCentralCrossRefPubMed
35.
Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ (2006) The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci 26(50):12852–12860CrossRefPubMed
36.
O’Neill J, McMahon SB, Undem BJ (2013) Chronic cough and pain: Janus faces in sensory neurobiology? Pulm Pharmacol Ther 26:476–485CrossRefPubMed
37.
Rush AM, Waxman SG (2004) PGE2 increases the tetrodotoxin-resistant Nav1.9 sodium current in mouse DRG neurons via G-proteins. Brain Res 1023(2):264–271CrossRefPubMed
38.
Ritter AM, Martin WJ, Thorneloe KS (2009) The voltage-gated sodium channel NaV1.9 is required for inflammation-based urinary bladder dysfunction. Neurosci Lett 452(1):28–32CrossRefPubMed
Metadata
Title
Targeting Voltage Gated Sodium Channels NaV1.7, NaV1.8, and NaV1.9 for Treatment of Pathological Cough
Authors
Yukiko Muroi
Bradley J. Undem
Publication date
01-02-2014
Publisher
Springer US
Published in
Lung / Issue 1/2014
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9533-x

Other articles of this Issue 1/2014

Lung 1/2014 Go to the issue

OriginalPaper

Stratification of Malignant Pleural Mesothelioma Prognosis Using Recursive Partitioning Analysis

OriginalPaper

RETRACTED ARTICLE: Protein–Protein Interaction Network Analysis in Chronic Obstructive Pulmonary Disease

OriginalPaper

Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos

OriginalPaper

Antituberculosis Treatment and Hepatotoxicity in Patients with Chronic Viral Hepatitis

OriginalPaper

Transforming Growth Factor-β1 and Tumor Necrosis Factor-α are Associated with Clinical Severity and Airflow Limitation of COPD in an Additive Manner

ReviewPaper

Cough in Asthma Is due to Eosinophilic Airway Inflammation: A Pro/Con Debate
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits